Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia.

Misra VP, Danchenko N, Maisonobe P, Lundkvist J, Hunger M.

J Clin Mov Disord. 2020 Feb 11;7:2. doi: 10.1186/s40734-020-0083-0. eCollection 2020.

2.

Endogenous APP accumulates in synapses after BACE1 inhibition.

Nigam SM, Xu S, Ackermann F, Gregory JA, Lundkvist J, Lendahl U, Brodin L.

Neurosci Res. 2016 Aug;109:9-15. doi: 10.1016/j.neures.2016.02.002. Epub 2016 Feb 22.

PMID:
26907521
3.

Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis.

Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Ström O.

Osteoporos Int. 2015 Oct;26(10):2401-11. doi: 10.1007/s00198-015-3253-4. Epub 2015 Aug 18.

4.

Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.

Georgievska B, Gustavsson S, Lundkvist J, Neelissen J, Eketjäll S, Ramberg V, Bueters T, Agerman K, Juréus A, Svensson S, Berg S, Fälting J, Lendahl U.

J Neurochem. 2015 Feb;132(4):477-86. doi: 10.1111/jnc.12937. Epub 2014 Sep 18.

5.

Changed membrane integration and catalytic site conformation are two mechanisms behind the increased Aβ42/Aβ40 ratio by presenilin 1 familial Alzheimer-linked mutations.

Wanngren J, Lara P, Ojemalm K, Maioli S, Moradi N, Chen L, Tjernberg LO, Lundkvist J, Nilsson I, Karlström H.

FEBS Open Bio. 2014 Apr 24;4:393-406. doi: 10.1016/j.fob.2014.04.006. eCollection 2014.

6.

The battle of Alzheimer's Disease - the beginning of the future Unleashing the potential of academic discoveries.

Lundkvist J, Halldin MM, Sandin J, Nordvall G, Forsell P, Svensson S, Jansson L, Johansson G, Winblad B, Ekstrand J.

Front Pharmacol. 2014 May 9;5:102. doi: 10.3389/fphar.2014.00102. eCollection 2014.

7.

Screening for abdominal aortic aneurysm in 65-year-old men remains cost-effective with contemporary epidemiology and management.

Svensjö S, Mani K, Björck M, Lundkvist J, Wanhainen A.

Eur J Vasc Endovasc Surg. 2014 Apr;47(4):357-65. doi: 10.1016/j.ejvs.2013.12.023. Epub 2014 Jan 31.

8.

Characterization of intermediate steps in amyloid beta (Aβ) production under near-native conditions.

Olsson F, Schmidt S, Althoff V, Munter LM, Jin S, Rosqvist S, Lendahl U, Multhaup G, Lundkvist J.

J Biol Chem. 2014 Jan 17;289(3):1540-50. doi: 10.1074/jbc.M113.498246. Epub 2013 Nov 13.

9.

Space and time resolved monitoring of airborne particulate matter in proximity of a traffic roundabout in Sweden.

Wilkinson KE, Lundkvist J, Netrval J, Eriksson M, Seisenbaeva GA, Kessler VG.

Environ Pollut. 2013 Nov;182:364-70. doi: 10.1016/j.envpol.2013.07.043. Epub 2013 Aug 23.

PMID:
23974166
10.
11.

Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data.

Niva C, Parkinson J, Olsson F, van Schaick E, Lundkvist J, Visser SA.

Eur J Clin Pharmacol. 2013 Jun;69(6):1247-60. doi: 10.1007/s00228-012-1459-3. Epub 2013 Jan 4.

PMID:
23288352
12.

Alzheimer's disease: presenilin 2-sparing γ-secretase inhibition is a tolerable Aβ peptide-lowering strategy.

Borgegård T, Gustavsson S, Nilsson C, Parpal S, Klintenberg R, Berg AL, Rosqvist S, Serneels L, Svensson S, Olsson F, Jin S, Yan H, Wanngren J, Jureus A, Ridderstad-Wollberg A, Wollberg P, Stockling K, Karlström H, Malmberg A, Lund J, Arvidsson PI, De Strooper B, Lendahl U, Lundkvist J.

J Neurosci. 2012 Nov 28;32(48):17297-305. doi: 10.1523/JNEUROSCI.1451-12.2012.

13.

Second generation γ-secretase modulators exhibit different modulation of Notch β and Aβ production.

Wanngren J, Ottervald J, Parpal S, Portelius E, Strömberg K, Borgegård T, Klintenberg R, Juréus A, Blomqvist J, Blennow K, Zetterberg H, Lundkvist J, Rosqvist S, Karlström H.

J Biol Chem. 2012 Sep 21;287(39):32640-50. Epub 2012 Jul 31.

14.

First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms.

Borgegard T, Juréus A, Olsson F, Rosqvist S, Sabirsh A, Rotticci D, Paulsen K, Klintenberg R, Yan H, Waldman M, Stromberg K, Nord J, Johansson J, Regner A, Parpal S, Malinowsky D, Radesater AC, Li T, Singh R, Eriksson H, Lundkvist J.

J Biol Chem. 2012 Apr 6;287(15):11810-9. doi: 10.1074/jbc.M111.305227. Epub 2012 Feb 13.

15.

BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system.

Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, Olsson M, Brinkmalm G, Lundkvist J, Jacobson LH, Perrot L, Neumann U, Borghys H, Mercken M, Dhuyvetter D, Jeppsson F, Blennow K, Portelius E.

PLoS One. 2012;7(2):e31084. doi: 10.1371/journal.pone.0031084. Epub 2012 Feb 6.

16.

Sulfonimidamides as sulfonamides bioisosteres: rational evaluation through synthetic, in vitro, and in vivo studies with γ-secretase inhibitors.

Sehgelmeble F, Janson J, Ray C, Rosqvist S, Gustavsson S, Nilsson LI, Minidis A, Holenz J, Rotticci D, Lundkvist J, Arvidsson PI.

ChemMedChem. 2012 Mar 5;7(3):396-9. doi: 10.1002/cmdc.201200014. Epub 2012 Feb 3. No abstract available.

PMID:
22307979
17.

Costs and clinical outcome of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from gastric cancer.

Hultman B, Lundkvist J, Glimelius B, Nygren P, Mahteme H.

Acta Oncol. 2012 Jan;51(1):112-21. doi: 10.3109/0284186X.2011.594809. Epub 2011 Nov 10.

PMID:
22070666
18.

Cost-effectiveness of intensive smoking cessation therapy among patients with small abdominal aortic aneurysms.

Mani K, Wanhainen A, Lundkvist J, Lindström D.

J Vasc Surg. 2011 Sep;54(3):628-36. doi: 10.1016/j.jvs.2011.02.055. Epub 2011 May 28.

19.

New tabletop SEM-EDS-based approach for cost-efficient monitoring of airborne particulate matter.

Wilkinson K, Lundkvist J, Seisenbaeva G, Kessler V.

Environ Pollut. 2011 Jan;159(1):311-318. doi: 10.1016/j.envpol.2010.08.024. Epub 2010 Oct 8.

PMID:
20933312
20.

The societal burden of poor persistence to treatment of osteoporosis in Sweden.

Landfeldt E, Lundkvist J, Ström O.

Bone. 2011 Feb;48(2):380-8. doi: 10.1016/j.bone.2010.09.012. Epub 2010 Sep 17.

PMID:
20850576
21.

The large hydrophilic loop of presenilin 1 is important for regulating gamma-secretase complex assembly and dictating the amyloid beta peptide (Abeta) Profile without affecting Notch processing.

Wanngren J, Frånberg J, Svensson AI, Laudon H, Olsson F, Winblad B, Liu F, Näslund J, Lundkvist J, Karlström H.

J Biol Chem. 2010 Mar 19;285(12):8527-36. doi: 10.1074/jbc.M109.055590. Epub 2010 Jan 27.

22.

Evidence for dimeric BACE-mediated APP processing.

Jin S, Agerman K, Kolmodin K, Gustafsson E, Dahlqvist C, Jureus A, Liu G, Fälting J, Berg S, Lundkvist J, Lendahl U.

Biochem Biophys Res Commun. 2010 Feb 26;393(1):21-7. doi: 10.1016/j.bbrc.2010.01.064. Epub 2010 Jan 25.

PMID:
20097169
23.

Screening for abdominal aortic aneurysm among patients referred to the vascular laboratory is cost-effective.

Mani K, Alund M, Björck M, Lundkvist J, Wanhainen A.

Eur J Vasc Endovasc Surg. 2010 Feb;39(2):208-16. doi: 10.1016/j.ejvs.2009.11.004. Epub 2009 Nov 25.

24.

Challenges in analysis and interpretation of cost data in vascular surgery.

Mani K, Lundkvist J, Holmberg L, Wanhainen A.

J Vasc Surg. 2010 Jan;51(1):148-54. doi: 10.1016/j.jvs.2009.08.042. Epub 2009 Nov 4. Review.

25.

Improved long-term survival after abdominal aortic aneurysm repair.

Mani K, Björck M, Lundkvist J, Wanhainen A.

Circulation. 2009 Jul 21;120(3):201-11. doi: 10.1161/CIRCULATIONAHA.108.832774. Epub 2009 Jul 6.

PMID:
19581497
26.

Health care costs for treatment of disseminated breast cancer.

Dahlberg L, Lundkvist J, Lindman H.

Eur J Cancer. 2009 Jul;45(11):1987-91. doi: 10.1016/j.ejca.2009.03.023. Epub 2009 Apr 22.

PMID:
19398326
27.

[Structured introduction of new drug therapies: valuable initiative--transparency required].

Lundkvist J, Henriksson F.

Lakartidningen. 2009 Jan 7-13;106(1-2):51. Swedish. No abstract available.

PMID:
19235324
28.

Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea.

Lundkvist J, Steffen R, Jönsson B.

J Travel Med. 2009 Jan-Feb;16(1):28-34. doi: 10.1111/j.1708-8305.2008.00270.x. Erratum in: J Travel Med. 2009 Mar-Apr;16(2):147.

29.

Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.

Kasteng F, Erlanson M, Hagberg H, Kimby E, Relander T, Lundkvist J.

Acta Oncol. 2008;47(6):1029-36. doi: 10.1080/02841860802120028.

PMID:
18607857
30.

Similar cost for elective open and endovascular AAA repair in a population-based setting.

Mani K, Björck M, Lundkvist J, Wanhainen A.

J Endovasc Ther. 2008 Feb;15(1):1-11. doi: 10.1583/07-2258.1.

PMID:
18254676
31.

The burden of rheumatoid arthritis and access to treatment: health burden and costs.

Lundkvist J, Kastäng F, Kobelt G.

Eur J Health Econ. 2008 Jan;8 Suppl 2:S49-60.

PMID:
18157732
32.

Health economic evaluations alongside clinical trials: a review of study protocols at the Swedish Medical Products Agency.

Lindfors A, Feltelius N, Lundkvist J.

Int J Technol Assess Health Care. 2007 Summer;23(3):392-6. Review.

PMID:
17579944
33.

Economic evaluations of leukemia: a review of the literature.

Kasteng F, Sobocki P, Svedman C, Lundkvist J.

Int J Technol Assess Health Care. 2007 Winter;23(1):43-53. Review.

PMID:
17234016
34.
35.

Gamma-secretase: a complex target for Alzheimer's disease.

Lundkvist J, Näslund J.

Curr Opin Pharmacol. 2007 Feb;7(1):112-8. Epub 2006 Dec 13. Review.

PMID:
17169612
36.
37.

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden.

Lundkvist J, Wilking N, Holmberg S, Jönsson L.

Breast Cancer Res Treat. 2007 May;102(3):289-99. Epub 2006 Oct 11.

PMID:
17033927
38.

Cost of hypoglycemia in patients with Type 2 diabetes in Sweden.

Jönsson L, Bolinder B, Lundkvist J.

Value Health. 2006 May-Jun;9(3):193-8.

39.

Cost-effectiveness of screening women for abdominal aortic aneurysm.

Wanhainen A, Lundkvist J, Bergqvist D, Björck M.

J Vasc Surg. 2006 May;43(5):908-14; discussion 914.

40.

The costs and benefits of regulations for reimbursement of new drugs.

Lundkvist J, Jönsson B, Rehnberg C.

Health Policy. 2006 Dec;79(2-3):337-44. Epub 2006 Mar 20.

PMID:
16549221
41.

Proton therapy of cancer: potential clinical advantages and cost-effectiveness.

Lundkvist J, Ekman M, Ericsson SR, Jönsson B, Glimelius B.

Acta Oncol. 2005;44(8):850-61.

PMID:
16332592
42.

Hypoxia requires notch signaling to maintain the undifferentiated cell state.

Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U, Bondesson M.

Dev Cell. 2005 Nov;9(5):617-28.

43.

gamma-Secretase complexes containing N- and C-terminal fragments of different presenilin origin retain normal gamma-secretase activity.

Strömberg K, Hansson EM, Laudon H, Bergstedt S, Näslund J, Lundkvist J, Lendahl U.

J Neurochem. 2005 Nov;95(3):880-90. Epub 2005 Aug 31.

44.

Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women.

Lundkvist J, Johnell O, Cooper C, Sykes D.

Osteoporos Int. 2006 Feb;17(2):201-11. Epub 2005 Jul 19.

PMID:
16027955
45.

Cost-effectiveness of new drugs: a systematic review of published evidence for new chemical entity drugs introduced on the Swedish market 1987-2000.

Lundkvist J, Jönsson B, Rehnberg C.

Int J Technol Assess Health Care. 2005 Spring;21(2):187-93. Review.

PMID:
15921058
46.

Cost-effectiveness of different screening strategies for abdominal aortic aneurysm.

Wanhainen A, Lundkvist J, Bergqvist D, Björck M.

J Vasc Surg. 2005 May;41(5):741-51; discussion 751.

47.

Economic evaluation of proton radiation therapy in the treatment of breast cancer.

Lundkvist J, Ekman M, Ericsson SR, Isacsson U, Jönsson B, Glimelius B.

Radiother Oncol. 2005 May;75(2):179-85.

PMID:
15885828
48.

Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy.

Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Lundkvist J.

Am Heart J. 2005 Feb;149(2):298-303.

PMID:
15846268
49.

The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly.

Lundkvist J, Ekman M, Kartman B, Carlsson J, Jönsson L, Lithell H.

J Hum Hypertens. 2005 Jul;19(7):569-76. Erratum in: J Hum Hypertens. 2005 Aug;19(8):662.

PMID:
15800664
50.

Overexpression of calsenilin enhances gamma-secretase activity.

Jo DG, Jang J, Kim BJ, Lundkvist J, Jung YK.

Neurosci Lett. 2005 Apr 11;378(1):59-64. Epub 2005 Jan 25.

PMID:
15763173

Supplemental Content

Loading ...
Support Center